Top-News
Biotechnologie USA

Catalyst Pharmaceuticals Inc Aktie

Aktie
WKN:  A0LCUL ISIN:  US14888U1016 US-Symbol:  CPRX
20,68 €
-0,25 €
-1,19%
12.12.24
Handeln Depot/Watchlist
Aktienanzahl *
118,12 Mio.
Marktkapitalisierung *
2,44 Mrd. €
Streubesitz
11,74%
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 15.07.2024

Catalyst Pharmaceuticals Inc News

21.03.24 - PR Newswire
Thinking about buying stock in Praxis Precision Medicines, Safety Shot, Catalyst Pharmaceuticals, Adicet Bio, or Exscientia?
Thinking about buying stock in Praxis Precision Medicines, Safety Shot, Catalyst Pharmaceuticals, Adicet Bio, or Exscientia? PR Newswire
19.03.24 - PR Newswire
Thinking about buying stock in Analog Devices,Catalyst Pharmaceuticals, QuickLogic, Synopsys, or Pagaya Technologies?
Thinking about buying stock in Analog Devices,Catalyst Pharmaceuticals, QuickLogic, Synopsys, or Pagaya Technologies? PR Newswire
15.05.23 - PR Newswire
Thinking about buying stock in JetBlue Airways, Hecla Mining, Catalyst Pharmaceuticals, Energy Transfer, or Ford?
Thinking about buying stock in JetBlue Airways, Hecla Mining, Catalyst Pharmaceuticals, Energy Transfer, or Ford? PR Newswire
21.11.22 - ESG-Aktien
Biotech – heiß wie nie: Catalyst Pharmaceuticals, BioNxt Solutions, Bayer
Biotechs liefern seit Jahren Antworten auf die drängendsten Fragen der Menschheit. Innovative Unternehmen setzen fortschrittliche Methoden dafür ein, den medizinischen ...
13.09.22 - PR Newswire
Thinking about buying stock in Core & Main, Catalyst Pharmaceuticals, Ironsource, Clovis Oncology, or Oncternal Therapeutics?
Thinking about buying stock in Core & Main, Catalyst Pharmaceuticals, Ironsource, Clovis Oncology, or Oncternal Therapeutics? PR Newswire
12.09.22 - PR Newswire
Catalyst Pharmaceuticals Set to Join S&P SmallCap 600
Catalyst Pharmaceuticals Set to Join S&P SmallCap 600 PR Newswire
03.06.21 - PR Newswire
Catalyst Pharmaceuticals, Inc.'s and KYE Pharmaceuticals' Lawsuit in Canadian Federal Court Quashes the Notice of Compliance (NOC) for Ruzurgi®
Catalyst Pharmaceuticals, Inc.'s and KYE Pharmaceuticals' Lawsuit in Canadian Federal Court Quashes the Notice of Compliance (NOC) for Ruzurgi® Canada NewsWire
22.03.21 - PR Newswire
Thinking about buying stock in Leap Therapeutics, Galmed Pharmaceuticals, Livexlive Media, Catalyst Pharmaceuticals, or Oramed Pharmaceuticals?
Thinking about buying stock in Leap Therapeutics, Galmed Pharmaceuticals, Livexlive Media, Catalyst Pharmaceuticals, or Oramed Pharmaceuticals? PR Newswire
13.08.20 - PR Newswire
Thinking about buying stock in AMAG Pharmaceuticals, Trevena Inc, Energous Corp, Catalyst Pharmaceuticals, or Plug Power?
Thinking about buying stock in AMAG Pharmaceuticals, Trevena Inc, Energous Corp, Catalyst Pharmaceuticals, or Plug Power? PR Newswire
27.09.19 - The Motley Fool
3 Top-Biotech-Aktien für September
Biotech-​Aktien entwickeln sich in den Sommermonaten nur selten gut, und 2019 war da keine Ausnahme. So ist beispielsweise der iShares Nasdaq Biotechnology ETF seit dem ...
13.09.19 - PR Newswire
Thinking about buying stock in AbbVie, Aurora Cannabis, Catalyst Pharmaceuticals, Fibrocell Science, or MER Telemanagement Solutions?
Thinking about buying stock in AbbVie, Aurora Cannabis, Catalyst Pharmaceuticals, Fibrocell Science, or MER Telemanagement Solutions? PR Newswire
26.02.16 - PR Newswire
Ryan & Maniskas, LLP Announces Investigation of Catalyst Pharmaceuticals, Inc.
Ryan & Maniskas, LLP Announces Investigation of Catalyst Pharmaceuticals, Inc. PR Newswire
17.02.16 - PR Newswire
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Catalyst Pharmaceuticals, Inc. (CPRX)
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Catalyst Pharmaceuticals, Inc. (CPRX) PR Newswire
28.10.13 - PR Newswire
Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces that a Securities Class Action has been Filed Against Catalyst Pharmaceutical Partners Inc.
Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces that a Securities Class Action has been Filed Against Catalyst Pharmaceutical Partners Inc. PR Newswire
14.11.12 - Aktiencheck
Catalyst Pharma Partners-Aktie: Kursziel gesenkt - Roth Capital
Die Analysten von Roth Capital stufen die Aktie von Catalyst Pharma Partners mit dem Rating "buy" ein. Das Kursziel werde von 3,00 USD auf 1,75 USD gesenkt. (Analyse vom ...
04.09.12 - Aktiencheck
Catalyst Pharma Partners-Aktie: stark unterbewertet - Global Biotech Investing
Nach Einschätzung der Experten von "Global Biotech Investing" holen sich Anleger mit der Aktie von Catalyst Pharma Partners die Aussicht auf eine Kapitalvervielfachung ins Depot. ...
20.07.10 - Aktiencheck
Catalyst Pharmaceuticals Partners Fantasie durch Kokain-Ersatzpräparat - Global Biotech Investing
Die Experten von "Global Biotech Investing" haben die Aktie von Catalyst Pharmaceuticals Partners in ihr Musterdepot aufgenommen. Die US-​Biotech-Gesellschaft habe die ...
29.11.07 - Aktiencheck
Catalyst Pharmaceuticals "market outperform" - Rodman & Renshaw
Rating-​Update: New York (aktiencheck.de AG) - Die Analysten von Rodman & Renshaw stufen die Aktie von Catalyst Pharmaceuticlas in einer Ersteinschätzung mit "market ...

Newssuche

Videos

newspaper
12.12.24
Technical Trading: Baumwolle Long, weil...
Cotton Long Typ: Turbo Open End WKN: VP6N8D Hebel: 3,80 Laufzeit: OpenEnd Einstieg: Market ... Mehr »